Literature DB >> 11205258

Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.

K Uefuji1, T Ichikura, N Shinomiya, H Mochizuki.   

Abstract

An increased expression of cyclooxygenase (COX)-2 has been observed in various cancers including gastric cancer. Although specific COX-2 inhibitors have a chemopreventive effect on colon cancer, their molecular mechanisms remain unclear. To clarify these mechanisms, we investigated the effects of JTE-522, a newly developed COX-2-specific inhibitor, on gastric cancer cell lines (MKN28 and MKN45). The baseline levels of COX-2 expression were higher in MKN45 than in MKN28. JTE-522 obviously suppressed the levels of COX-2 mRNA, COX-2 protein and PGE2 at a dose of 250 microM in both cancer cells. Apoptosis was induced at 24 hours after treatment with JTE-522 (250 microM) in both cancer cells. To determine the mechanisms of apoptosis induction by JTE-522, the time course of the cell cycle and the apoptosis-related protein levels were examined. An increase in the G1 phase and a decrease in the S phase were observed prior to apoptosis. Moreover, an increase of c-myc protein and a decrease of bcl-2 protein were observed in both cells treated with JTE-522. These findings suggested that JTE-522 could induce apoptosis by blocking the cell cycle, enhancing c-myc expression and diminishing bcl-2 expression. JTE-522 also suppressed proliferation activity in both cell lines. These effects of JTE-522 were more dramatic in MKN45 than in MKN28. Since JTE-522 strongly suppresses cell growth by inducing apoptosis in gastric cancer cell lines, it may therefore serve as a chemopreventive agent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205258

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

2.  Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.

Authors:  Ying-Wei Xue; Qi-Fan Zhang; Zhi-Bing Zhu; Qi Wang; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

3.  Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor.

Authors:  Jiro Okami; Shoji Nakamori; Nobuaki Hiraoka; Masanori Tsujie; Nobuyasu Hayashi; Hirofumi Yamamoto; Yoshiyuki Fujiwara; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.

Authors:  Yu Baoping; Hu Guoyong; Yu Jieping; Ran Zongxue; Luo Hesheng
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

5.  Cyclooxygenase (COX)-2 and granulosa cell apoptosis in vitro.

Authors:  Angela S Caffrey; William C Patton; Johannah U Corselli; Ron E Swensen; Alan King; Philip J Chan
Journal:  J Assist Reprod Genet       Date:  2002-12       Impact factor: 3.412

6.  Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

Authors:  J Ostrowski; T Wocial; H Skurzak; W Bartnik
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

Review 7.  Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract.

Authors:  Debora Compare; Olga Nardone; Gerardo Nardone
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-09

8.  Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells.

Authors:  Quanxin Wang; Yoshiyuki Takei; Osamu Kobayashi; Taro Osada; Sumio Watanabe
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.